scholarly journals Association study of the beta-adrenergic receptor genetic variant Gly389Arg and fluoxetine response in major depression

2020 ◽  
Vol 9 ◽  
pp. 1781
Author(s):  
Negar Firouzabadi ◽  
Roja Asadpour ◽  
Kamiar Zomorrodian
Keyword(s):  
Rating Scale ◽  
Response To Treatment ◽  
Adrenergic System ◽  
Major Depressive ◽  
Pcr Rflp ◽  
Dsm Iv ◽  
And Behavior ◽  
Hamilton Rating Scale ◽  
Beta Gene ◽  
Arg389gly Polymorphism

Background: Pharmacogenetics has proven role in the treatment of different illnesses. Patients with special genotypes may achieve a better response to a specific drug. On the other hand, genetic parameters markedly contribute to the development of major depressive disorder (MDD). The significance of adrenergic system compartments in cognition and behavior, and their role in etiology of depression denote that adrenergic receptors beta gene polymorphism(s) might also have an association with drug response. Thus this study aims to evaluate the association between β1AR gene polymorphisms, G1165C, Arg389Gly and response to fluoxetine in MDD patients. Materials and Methods: Among different antidepressants, we focused on fluoxetine as it is prescribed frequently in MDD and belongs to one of the most efficient antidepressant categories with minimum side effects. MDD was diagnosed at study entry using DSM-IV criteria. One hundred and one new MDD patients were treated with fluoxetine for a period of 6 weeks. A 50% decrease in Hamilton Rating Scale for Depression (HRSD) was considered as response to treatment. Genotyping of G1165C polymorphism was performed by PCR-RFLP method. Results: Results of the study indicated no significant relationship between β1AR polymorphism and the patient’s response to fluoxetine neither at genotypic nor allelic level (P=0.568). Conclusion: Our study did not support the hypothesis of involvement of β1AR Arg389Gly polymorphism and response to fluoxetine in MDD patients. [GMJ.2020;9:e1781]

scholarly journals Beta Adrenoceptor Polymorphism and Clinical Response to Sertraline in Major Depressive Patients

2017 ◽  
Vol 20 ◽  
pp. 1 ◽  
Author(s):  
Negar Firouzabadi ◽  
Roshanak Raeesi ◽  
Kamiar Zomorrodian ◽  
Ehsan Bahramali ◽  
Ilnaz Yavarian
Keyword(s):  
Clinical Response ◽  
Rating Scale ◽  
Response To Treatment ◽  
Noradrenergic System ◽  
Newly Diagnosed ◽  
Major Depressive ◽  
Beta Adrenoceptor ◽  
Receptor Signalling ◽  
Depressive Patients ◽  
Hamilton Rating Scale

Purpose: The adrenoceptor family, as one of the main contributors in regulating the noradrenergic system, has been studied in involvement of depression and its treatment. A functional polymorphism of G1165C on beta adrenoceptor (βAR) enhances post receptor signalling and is assumed to be involved in pharmacotherapy of depression. The aim of the present study was to discern the influence of G1165C polymorphism in the β1AR gene on individual differences in response to sertraline. Methods: One hundred newly diagnosed patients completed 6 weeks of sertraline treatment. Response to treatment was defined as a 50% decrease in Hamilton Rating Scale for depression (HRSD). Results: The patients who carried CC genotype responded five times more to sertraline comparing with other variants (P=0.005; OR=5.7; 95%CI=1.4-23.9). Moreover, carriers of C allele responded three times more to sertraline than patients with the G allele (P=0.001; OR= 3.3; 95%CI= 1.72-6.50). Conclusion: In conclusion, our results support the hypothesis that genetic variation of β1AR might influence clinical response to sertraline. This article is open to POST-PUBLICATION REVIEW. Registered readers (see “For Readers”) may comment by clicking on ABSTRACT on the issue’s contents page.

scholarly journals Psychotherapy alone and combined with pharmacotherapy in the treatment of depression

2004 ◽  
Vol 185 (1) ◽  
pp. 37-45 ◽  
Author(s):  
Frans De Jonghe ◽  
Mariëlle Hendricksen ◽  
Gerda Van Aalst ◽  
Simone Kool ◽  
Vjaap Peen ◽  
...  
Keyword(s):  
Rating Scale ◽  
Combined Therapy ◽  
Randomised Clinical Trial ◽  
Symptom Checklist ◽  
Major Depressive ◽  
Supportive Psychotherapy ◽  
Treatment Of Depression ◽  
Ambulatory Patients ◽  
Dsm Iv ◽  
Hamilton Rating Scale

BackgroundThe relative efficacy of psychotherapy and combined therapy in the treatment of depression is still a matter of debate.AimsTo investigate whether combined therapy has advantages over psychotherapy alone.MethodA 6-month randomised clinical trial compared Short Psychodynamic Supportive Psychotherapy (n = 106) with combined therapy (n=85) in ambulatory patients with mild or moderate major depressive disorder diagnosed using DSM-IV criteria. Antidepressants were prescribed according to a protocol providing four successive steps in case of intolerance or inefficacy: venlafaxine, selective serotonin reuptake inhibitor, nortriptyline and nortriptyline plus lithium. Efficacy was assessed using the 17-item Hamilton Rating Scale for Depression, the Clinical Global Impression of Severity and of Improvement, and the depression sub-scale of the Symptom Checklist.ResultsThe advantages of combining antidepressants with psychotherapy were equivocal. Neither the treating clinicians nor the independent observers were able to ascertain them, but the patients experienced them clearly.ConclusionsThe advantages of combining antidepressants with psychotherapy are equivocal.

Reward Sensitivity and Response to Treatment in Major Depression

2009 ◽  
Vol 24 (S1) ◽  
pp. 1-1
Author(s):  
E. Vrieze ◽  
D. Pizzagalli ◽  
K. Demyttenaere ◽  
S. Claes
Keyword(s):  
Healthy Subjects ◽  
Rating Scale ◽  
Reward Sensitivity ◽  
Response To Treatment ◽  
Control Group ◽  
Percent Reduction ◽  
Major Depressive ◽  
Reward Responsiveness ◽  
Reward Dependence ◽  
Dsm Iv

Rationale:Anhedonia, or the lack of reactivity to a pleasurable stimuli is expressed as reduced reward sensitivity in patients with major depressive disorder (MDD) (1). Reward experience might discriminate between depressed patients who respons to treatment and those who do not (2).Objective:The purpose of this study was to test the hypothesis that patients non-responsive to treatment show reduced reward sensitivity compared to responsive patients.Method:A probabilistic computer task was used to measure reward sensitivity objectively (3). Twenty-eight medicated inpatients meeting DSM-IV criteria for MDD performed the reward task within the first week after submission and again after eight weeks. The response to treatment was assessed with the Hamilton Depression rating Scale (HDRS). Patients with scores less that ten or a fifty percent reduction on the HDRS after 8 weeks were considered responders to treatment. Sixteen healthy subjects were recruited as controls.Results:When considering reward sensitivity at baseline, the control group was significantly more sensitive to reward than the responders group and the non-responders group, who were the least reward sensitive (F = 11.88; p < 0.01). After 8 weeks, responders showed an almost similar reward dependence to controls on the task, however non-responders still preformed significantly worse compared to both responders and controls (F= 8.71; p< 0.01).Conclusion:These results support the hypothesis that impairment of reward responsiveness might influence response to treatment in patients with MDD.

scholarly journals Double-blind clonazepam vs placebo in panic disorder treatment

2000 ◽  
Vol 58 (4) ◽  
pp. 1025-1029 ◽  
Author(s):  
ALEXANDRE MARTINS VALENÇA ◽  
ANTONIO EGIDIO NARDI ◽  
ISABELLA NASCIMENTO ◽  
MARCO A. MEZZASALMA ◽  
FABIANA L. LOPES ◽  
...  
Keyword(s):  
Panic Disorder ◽  
Rating Scale ◽  
Panic Attacks ◽  
Fixed Dose ◽  
Fisher Exact Test ◽  
Double Blind ◽  
Exact Test ◽  
Dsm Iv ◽  
Disorder Treatment ◽  
Hamilton Rating Scale

OBJECTIVE: To assess the effectiveness of clonazepam, in a fixed dose (2 mg/day), compared with placebo in the treatment of panic disorder patients. METHOD: 24 panic disorder patients with agoraphobia were randomly selected. The diagnosis was obtained using the structured clinical interview for DSM-IV . All twenty-four subjects were randomly assigned to either treatment with clonazepam (2 mg/day) or placebo, during 6 weeks. Efficacy assessments included: change from baseline in the number of panic attacks; CGI scores for panic disorder; Hamilton rating scale for anxiety; and panic associated symptoms scale. RESULTS: At the therapeutic endpoint, only one of 9 placebo patients (11.1%) were free of panic attacks, compared with 8 of 13 (61.5%) clonazepam patients (Fisher exact test; p=0,031). CONCLUSION: the results provide evidence for the efficacy of clonazepam in panic disorder patients.

Effects of ECT on Prolactin, LH, FSH and Testosterone in Males with Major Depressive Illness*

1989 ◽  
Vol 34 (8) ◽  
pp. 814-817 ◽  
Author(s):  
A.J. Cooper ◽  
R. Finlayson ◽  
V.R. Velamoor ◽  
R.V. Magnus ◽  
Z. Cernovsky
Keyword(s):  
Luteinizing Hormone ◽  
Sexual Functioning ◽  
Rating Scale ◽  
Follicle Stimulating Hormone ◽  
Depressive Illness ◽  
Serum Prolactin ◽  
Major Depressive ◽  
Treatment Changes ◽  
Severity Of Depression ◽  
Hamilton Rating Scale

Fourteen males with major depressive illness (DSM-III) received a course of electroconvulsive therapy (ECT). Serum prolactin (PRL), luteinizing hormone (LH), follicle stimulating hormone (FSH) and testosterone (T), were measured 15 minutes before and 15 minutes after each treatment. The severity of depression was assessed with the Hamilton Rating Scale for Depression (HRSD) two to three days before the first and two to three days following the last treatment. Post-ECT levels of PRL and LH were significantly higher than pre-ECT levels across every treatment. Changes in FSH and testosterone were not significant. There were no relationships between hormone levels (first versus last ECT) and severity of depression, including sexual functioning. It is argued that the relatively greater increases of LH than FSH is due to an acute antidopaminergic action of ECT which acts selectively on the secretion of the former. The blunted testosterone response to the increase of gonadotropins may be due to ECT-induced hyperprolactinemia.

scholarly journals Empirical evidence for definitions of episode, remission, recovery, relapse and recurrence in depression: a systematic review

2018 ◽  
Vol 28 (5) ◽  
pp. 544-562 ◽  
Author(s):  
P. L. de Zwart ◽  
B. F. Jeronimus ◽  
P. de Jonge
Keyword(s):  
Depressive Symptoms ◽  
Depressive Episode ◽  
Rating Scale ◽  
Driving Forces ◽  
Evidence Based ◽  
Limited Data ◽  
Major Depressive ◽  
The Past ◽  
Duration Threshold ◽  
Hamilton Rating Scale

Aims.For the past quarter of a century, Frank et al.’s (1991) consensus-based definitions of major depressive disorder (MDD) episode, remission, recovery, relapse and recurrence have been the paramount driving forces for consistency in MDD research as well as in clinical practice. This study aims to review the evidence for the empirical validation of Frank et al.’s proposed concept definitions and to discuss evidence-based modifications.Methods.A literature search of Web of Science and PubMed from 1/1/1991 to 08/30/2017 identified all publications which referenced Frank et al.’s request for definition validation. Publications with data relevant for validation were included and checked for referencing other studies providing such data.Results.A total of 56 studies involving 39 315 subjects were included, mainly presenting data to validate the severity and duration thresholds for defining remission and recovery. Most studies indicated that the severity threshold for defining remission should decrease. Additionally, specific duration thresholds to separate remission from recovery did not add any predictive value to the notion that increased remission duration alleviates the risk of reoccurrence of depressive symptoms. Only limited data were available to validate the severity and duration criteria for defining a depressive episode.Conclusions.Remission can best be defined as a less symptomatic state than previously assumed (Hamilton Rating Scale for Depression, 17-item version (HAMD-17) ⩽4 instead of ⩽7), without applying a duration criterion. Duration thresholds to separate remission from recovery are not meaningful. The minimal duration of depressive symptoms to define a depressive episode should be longer than 2 weeks, although further studies are required to recommend an exact duration threshold. These results are relevant for researchers and clinicians aiming to use evidence-based depression outcomes.

Spa Therapy in Anxiety Disorder in a 8 Week Comparative and Randomized Multicentre Study on 237 Patients

2009 ◽  
Vol 24 (S1) ◽  
pp. 1-1
Author(s):  
O. Dubois
Keyword(s):  
Anxiety Disorder ◽  
Multicentre Study ◽  
Rating Scale ◽  
Therapy Group ◽  
Spa Therapy ◽  
Generalized Anxiety ◽  
Generalized Anxiety Disorders ◽  
Spa Treatment ◽  
Dsm Iv ◽  
Hamilton Rating Scale

We compared spa therapy-like balneotherapy treatment with Paroxetine by means of a multicentre, comparative, randomized 8-week study. At least 200 patients fitting the diagnosed criteria of generalized anxiety disorder (DSM IV) were to be recruited. They were carried out by an independent, fully-trained and specialized assessor.The total score on the HAM-A scale (Hamilton Rating Scale for Anxiety) was the main measure for efficiency.There were 237 patients altogether attending in ambulatory who were admitted into the 4 French centres and joined the protocol. 117 were divided up by drawing lots into the Spa Therapy group and 120 into the Paroxetine group.All 207 patients were able to be assessed at W8. The HAM-A scores at W8 showed significant improvement in the Spa Therapy group compared to the Paroxetine group (t = 3.04 p≤ 0.0001). Remission and the rate of improvement (superior or equal to 50%) were markedly higher in the Spa Therapy group.Other analyses stemming from this assessment enrich the results, with complemetary information on the importance of a spa treatment course prescribed in a psychiatric aim.In conclusion, the Spa Therapy-based Balneotherapy treatment is one that has shown specific efficiency in generalized anxiety disorders. Its profile of being well-tolerated and well-accepted by the patients may enable to introduce it regularly in GAD, particularly for people who are resistent to, dependent on or have difficulty in tolerating pharmacology or psychotherapy treatments.

scholarly journals Crocus sativus L. versus Citalopram in the Treatment of Major Depressive Disorder with Anxious Distress: A Double-Blind, Controlled Clinical Trial

2016 ◽  
Vol 50 (04) ◽  
pp. 152-160 ◽  
Author(s):  
A. Ghajar ◽  
S. Neishabouri ◽  
N. Velayati ◽  
L. Jahangard ◽  
N. Matinnia ◽  
...  
Keyword(s):  
Major Depressive Disorder ◽  
Depressive Disorder ◽  
Rating Scale ◽  
Crocus Sativus ◽  
Controlled Clinical Trial ◽  
P Value ◽  
Major Depressive ◽  
Significant Difference ◽  
Hamilton Rating Scale ◽  
Crocus Sativus L

Abstract Introduction: Saffron (Crocus sativus L.) has demonstrated antidepressant effects in clinical studies and extensive anxiolytic effects in experimental animal models. Methods: 66 patients with major depressive disorder accompanied by anxious distress were randomly assigned to receive either saffron (30 mg/day) or citalopram (40 mg/day) for 6 weeks. Hamilton Rating Scale for Depression (HAM-D) and Hamilton Rating Scale for Anxiety (HAM-A) were used to assess treatment effect during the trial. Results: 60 participants finished the study. Patients who received either saffron or citalopram showed significant improvement in scores of the Hamilton Rating Scale for Depression (P-value<0.001 in both groups) and Hamilton Rating Scale for Anxiety (P-value<0.001 in both groups). Comparison of score changes between the 2 trial arms showed no significant difference (P-value=0.984). Frequency of side effects was not significantly different between the 2 groups. Discussion: The present study indicates saffron as a potential efficacious and tolerable treatment for major depressive disorder with anxious distress.

Is There a Delay in the Onset of the Antidepressant Effect of Electroconvulsive Therapy?

1994 ◽  
Vol 164 (1) ◽  
pp. 106-109 ◽  
Author(s):  
Colin R. Rodger ◽  
Allan I. F. Scott ◽  
Lawrence J. Whalley
Keyword(s):  
Major Depressive Disorder ◽  
Depressive Disorder ◽  
Electroconvulsive Therapy ◽  
Rating Scale ◽  
Antidepressant Effect ◽  
Major Depressive ◽  
Depressed Patients ◽  
Severity Of Depression ◽  
Drug Free ◽  
Hamilton Rating Scale

The severity of depression in 11 drug-free unipolar patients diagnosed with definite major depressive disorder was assessed using the Hamilton Rating Scale for Depression during a course (5–10 treatments) of bilateral electroconvulsive therapy (ECT). The degree of improvement after three treatments of ECT was six times greater than the improvement that occurred over the remainder of the course. Although depressed patients who recover with ECT require repeated treatments, the treatments early in a course of ECT can have marked antidepressant effect.

scholarly journals Use of liothyronine in preventing electroconvulsive therapy-induced memory impairment: evaluation

2013 ◽  
Vol 37 (2) ◽  
pp. 49-53 ◽  
Author(s):  
Abbas Masoudzadeh ◽  
Seyyed Taha Yahyavi ◽  
Hooman Rashidi ◽  
Reza Ali Mohammadpour ◽  
Reza Kiani
Keyword(s):  
Electroconvulsive Therapy ◽  
Rating Scale ◽  
Meta Analysis ◽  
Major Depressive ◽  
Wechsler Memory Scale ◽  
Sixth Session ◽  
Multicentre Research ◽  
Hamilton Rating Scale ◽  
Cognitive Side Effects ◽  
Adequate Data

Aims and methodTo evaluate the effect of liothyronine administration on the cognitive side-effects of electroconvulsive therapy (ECT), 30 participants with major depressive disorder that were suitable candidates for ECT were randomly allocated to either a liothyronine or a placebo group. Participants in the liothyronine group received a daily 50 μg dose for the whole period of receiving ECT starting the day before ECT, whereas the other group received a placebo. The Hamilton Rating Scale for Depression (HRSD) and the Wechsler Memory Scale – revised (WMS-R) were used for evaluating mood and memory before the first ECT session and after the sixth session (the HRSD was also used after the third session).ResultsThe results indicated that after the sixth ECT session, participants that received liothyronine achieved significantly better scores on the HRSD and WMS-R.Clinical implicationsFurther studies with a larger number of participants, through multicentre research projects, are indicated to obtain adequate data for meta-analysis and systematic review.

Sign in / Sign up

Export Citation Format

Share Document